anti-interleukin-6 - for COVID-19 severe or critically   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.09 [0.76, 1.56]< 10%4 studies (4/-)32.7 %highnot evaluable lowcrucial-
clinical improvement 1.21 [0.96, 1.52]> 19%4 studies (4/-)94.8 %highnot evaluable lowimportant-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %some concernnot evaluable moderateimportant-
clinical worsening 1.11 [0.59, 2.09]< 10%1 study (1/-)37.4 %lownot evaluable highimportant-
death or ventilation 0.61 [0.39, 0.95]< 17%3 studies (3/-)98.6 %highnot evaluable lowimportant-
ventilation 0.27 [0.14, 0.55]< 10%2 studies (2/-)100.0 %highnot evaluable lowimportant-
off oxygenation 1.46 [0.79, 2.68]> 128%2 studies (2/-)88.7 %highnot evaluable lownon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 91 91